

Uracil: Pyrimidine-2,4(1*H*,3*H*)-dione.

C<sub>4</sub>H<sub>4</sub>N<sub>2</sub>O<sub>2</sub> 112.09

Lamivudine-uracil derivative: 1-[(2*RS*,5*SR*)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]uracil.

C<sub>8</sub>H<sub>10</sub>N<sub>2</sub>O<sub>4</sub>S 230.24

Cytosine: 4-Aminopyrimidin-2(1*H*)-one.

C<sub>4</sub>H<sub>5</sub>N<sub>3</sub>O 111.10

Lamivudine-*S*-sulfoxide: 1-[(2*R*,3*S*,5*S*)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine *S*-oxide.

C<sub>8</sub>H<sub>11</sub>N<sub>3</sub>O<sub>4</sub>S 245.26

Lamivudine-*R*-sulfoxide: 1-[(2*R*,3*R*,5*S*)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine *S*-oxide.

C<sub>8</sub>H<sub>11</sub>N<sub>3</sub>O<sub>4</sub>S 245.26

Lamivudine carboxylic acid: (2*RS*,5*SR*)-5-(Cytosine-1-yl)-1,3-oxathiolane-2-carboxylic acid.

C<sub>8</sub>H<sub>9</sub>N<sub>3</sub>O<sub>4</sub>S 243.24


Lamivudine diastereomer: 1-[(2*S*,5*S*)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.

C<sub>8</sub>H<sub>11</sub>N<sub>3</sub>O<sub>3</sub>S 229.26

Salicylic acid: 2-Hydroxybenzoic acid.

C<sub>7</sub>H<sub>6</sub>O<sub>3</sub> 138.12

## Abacavir Sulfate



(C<sub>14</sub>H<sub>18</sub>N<sub>6</sub>O)<sub>2</sub> · H<sub>2</sub>SO<sub>4</sub> 670.74

2-Cyclopentene-1-methanol, 4-[2-amino-6-(cyclopropylamino)-9*H*-purin-9-yl]-, (1*S*-*cis*)-, sulfate (salt) (2:1);

(1*S*,4*R*)-4-[2-Amino-6-(cyclopropylamino)-9*H*-purin-9-yl]-2-cyclopentene-1-methanol sulfate (salt) (2:1) [188062-50-2].

### DEFINITION

Abacavir Sulfate contains NLT 97.0% and NMT 102.0% of (C<sub>14</sub>H<sub>18</sub>N<sub>6</sub>O)<sub>2</sub> · H<sub>2</sub>SO<sub>4</sub>, calculated on the anhydrous and solvent-free basis.

### IDENTIFICATION

- **A. INFRARED ABSORPTION** (197K)
- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *System suitability solution*, obtained as directed in the test for *Organic Impurities, Procedure 2*.
- **C. IDENTIFICATION TESTS—GENERAL, Sulfate** (191)  
*Sample solution:* 5 mg/mL

### ASSAY

- **PROCEDURE**  
*Mobile phase:* Acetonitrile, phosphoric acid, and water (20:1:180)  
*Standard solution:* 0.04 mg/mL of USP Abacavir Sulfate RS in water  
*Sample solution:* 0.04 mg/mL of Abacavir Sulfate in water  
**Chromatographic system**  
 (See *Chromatography* (621), *System Suitability*.)

**Mode:** LC

**Detector:** UV 254 nm

**Column:** 4.6-mm × 5-cm; 5-μm packing L1

**Column temperature:** 30°

**Flow rate:** 1 mL/min

**Injection size:** 20 μL

**System suitability**

**Sample:** *Standard solution*

**Suitability requirements**

**Relative standard deviation:** NMT 1.5%

**Analysis**

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of (C<sub>14</sub>H<sub>18</sub>N<sub>6</sub>O)<sub>2</sub> · H<sub>2</sub>SO<sub>4</sub> in the portion of Abacavir Sulfate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak area of abacavir from the *Sample solution*

$r_S$  = peak area of abacavir from the *Standard solution*

$C_S$  = concentration of USP Abacavir Sulfate RS in the *Standard solution* (mg/mL)

$C_U$  = concentration of Abacavir Sulfate in the *Sample solution* (mg/mL)

**Acceptance criteria:** 97.0%–102.0% on the anhydrous and solvent-free basis

### IMPURITIES

#### Inorganic Impurities

- **RESIDUE ON IGNITION** (281): NMT 0.2%

#### Organic Impurities

- **PROCEDURE 1: RELATED COMPOUNDS**

**Solution A:** Trifluoroacetic acid and water (0.05:99.95)

**Solution B:** Methanol and water (17:3)

**Mobile phase:** See the gradient table below.

Time (min)	Solution A (%)	Solution B (%)
0	95	5
20	70	30
35	10	90
35.1	95	5
50	95	5

**System suitability solution:** 0.25 mg/mL of USP Abacavir Related Compounds Mixture RS in water

**Sample solution:** 0.25 mg/mL of Abacavir Sulfate in water

#### Chromatographic system

(See *Chromatography* (621), *System Suitability*.)

**Mode:** LC

**Detector:** UV 254 nm

**Column:** 3.9-mm × 15-cm; 5-μm packing L1

**Column temperature:** 30°

**Flow rate:** 1 mL/min

**Injection size:** 20 μL

**System suitability**

**Sample:** *System suitability solution*

**Suitability requirements**

**Resolution:** NLT 1.5 between abacavir and *trans*-abacavir

**Analysis**

**Sample:** *Sample solution*

Calculate the percentage of each impurity in the portion of Abacavir Sulfate taken:

$$\text{Result} = (r_U/r_T) \times 100$$

$r_U$  = peak area of each impurity from the *Sample solution*

$r_T$  = sum of the areas of all the peaks from the *Sample solution*